Scientists Use Artificial Intelligence To Spot Alzheimer's Before Onset of Sy...

皇后

http://bigthink.com/articles/sci ... e-onset-of-symptoms

“If you can tell from a group of of individuals who is the one that will develop the disease, one can better test new medications that could be capable of preventing the disease,” said co-lead study author Dr. Pedro Rosa-Neto, an associate professor of neurology, neurosurgery and psychiatry at McGill University, to Live Science.

The algorithm works by searching brain scans for the buildup of amyloid, a protein that accumulates in the brains of people who develop mild cognitive impairment and, later, dementia. Amyloid starts accumulating in the brain years, or sometimes decades, before the onset of dementia, and it does so at differents rates and locations in the brain. What’s more, not everyone with amyloid buildup necessarily develops cognitive impairment. This has made spotting the development of dementia difficult for scientists.

Machine learning could make it much easier.

Using hundreds of PET scans available through the Alzheimer’s Disease Neuroimaging Initiative (ADNI), scientists trained an algorithm to spot signs of dementia by having it first analyze the amyloid buildup in the scans of patients who had mild cognitive impairment. They then showed it brain scans taken before patients had developed the disease.

(Summary of the steps followed to train the algorithm to predict the progression of dementia.)

Scientists then presented the algorithm with a new set of brain scans, some of which were from patients who currently had mild cognitive impairment. All of the scans, however, were taken before any of the patients had developed the disease. The algorithm was able to predict which patients would end up impaired with an accuracy of 84 percent.

“This is an example how big data and open science brings tangible benefits to patient care,” said  Rosa-Neto to McGill News.

The biggest benefit to patient care could be improved clinical trials studying the effectiveness of drugs for Alzheimer’s, the most common form of dementia.

“By using this tool, clinical trials could focus only on individuals with a higher likelihood of progressing to dementia within the time frame of the study,” said Dr. Serge Gauthier, the study’s co-lead author, to McGill News. “This will greatly reduce the cost and the time necessary to conduct these studies.”

Research was funded by the Canadian Consortium on Neurodegeneration in Aging (CCNA) and the Canadian Institutes of Health Research.